74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Cerus Corp
Closed
SectorHealthcare
1.33 -1.48
Overview
Share price change
24h
Min
1.33
Max
1.41
Income | 374K -2.6M |
|---|---|
Sales | 4.8M 51M |
EPS | -0.01 |
Profit margin | -5.042 |
Employees | 614 |
EBITDA | 120K -66K |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +228.47% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -96M 240M |
|---|---|
Previous open | 2.81 |
Previous close | 1.33 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Cerus Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cerus Corp Forecast
Price Target
By TipRanks
228.47% upside
12 Months Forecast
Average 4.5 USD 228.47%
High 5 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forCerus Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
